The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation

The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation

Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow the clinician to consider therapy modification befor...

Full description

Bibliographic Details
Main Authors: P.H.C. França, H.S.M. Coelho, C.E. Brandão, J.A. Segadas, R.F. Quintaes, F.J. Carrilho, S. Ono-Nita, A.A. Mattos, C. Tovo, V.S. Gouvea, E. Sablon, B.O.M. Vanderborght
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2007-12-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Hepatitis B
Antiviral therapy
Lamivudine
Drug resistance
YMDD variants
Hepatitis B virus
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003

Similar Items